Merck and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017

Thursday, May 18, 2017 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

DARMSTADT, Germany and NEW YORK, May 17, 2017 /PRNewswire/ --

Not intended for

US, Canada and UK-based media 

  • A total of 13 abstracts across seven hard-to-treat cancers highlight the progress of avelumab as a
    monotherapy and potential novel combination treatment option  
  • New data in metastatic Merkel cell carcinoma and previously treated metastatic urothelial carcinoma, following recent US FDA accelerated approvals 

Merck and Pfizer today announced that 13 avelumab* abstracts across seven challenging tumor types will be featured at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting held June 2-6, 2017 in Chicago, IL. Key presentations include data for avelumab in first-line metastatic Merkel cell carcinoma (mMCC) and in previously treated metastatic urothelial carcinoma (UC), as well as results from the Phase Ib trial investigating avelumab in combination with the tyrosine kinase inhibitor axitinib, in advanced renal cell carcinoma (RCC).

     (Logo: )

"Our ASCO presence adds to what has already been a momentous year for the alliance, coming shortly after the US FDA granted two accelerated approvals for avelumab," said Luciano Rossetti, M.D., Executive Vice President, Global Head of Research & Development at the biopharma business of Merck, which in the US and Canada operates as EMD Serono. "We're particularly excited to share the latest avelumab data in both metastatic Merkel cell carcinoma in the first-line setting and previously treated metastatic urothelial carcinoma with the cancer community."

"Our data at ASCO this year underscore the potential of avelumab as a monotherapy treatment, as well as part of combination regimens," said Chris Boshoff, M.D., PhD, Senior Vice President and Head of Immuno-Oncology, Early Development, Translational Oncology, Pfizer Global Product Development. "Now with accelerated approvals in two indications for avelumab in the US, we are entering the next chapter of our clinical development program to provide meaningful new treatment options for patients who need them most."

Highlights of avelumab data at ASCO 2017 include the following:

  • Preliminary data from the ongoing JAVELIN Merkel 200 trial, an open-label, multicenter study conducted in first-line mMCC investigating avelumab in patients who had no prior systemic treatment for mMCC, will be presented for the first time at a medical congress.
  • Data from a pooled analysis of two metastatic UC cohorts of the JAVELIN Solid Tumor trial, a Phase Ib, open-label, single-arm, multicenter study of avelumab in the treatment of various solid tumors, will be presented.
  • An oral presentation of results from the JAVELIN Renal 100 trial, a Phase Ib, open-label study evaluating the clinical activity and safety of the combination of avelumab and axitinib for the first-line treatment of advanced RCC.
  • Beyond mMCC, metastatic UC and RCC, the Merck-Pfizer Alliance will also showcase avelumab abstracts in non-small cell lung cancer, metastatic castrate-resistant prostate cancer, locally advanced squamous cell carcinoma of the head and neck and relapsed or refractory diffuse large B-cell lymphoma, as well as updated safety data in solid tumors.

The alliance's rapidly accelerating JAVELIN clinical development program now involves at least 30 clinical programs, including nine Phase III trials, and more than 5,200 patients across more than 15 tumor types. Results from JAVELIN program trials have supported two FDA accelerated approvals in 2017.

A list of accepted avelumab abstracts is included below. The abstracts are also available on the ASCO website.

                                      Abstract ID /     Presentation
    Title                Lead Author  Poster No.         Date / Time               Session
    Oral Presentations

    Renal Cell           Choueiri TK          4504    Monday, June 5         Genitourinary
    Carcinoma                                        8:00-11:00 a.m.  (Nonprostate) Cancer
    (JAVELIN Renal

    avelumab +
    axitinib therapy
    in patients with                  
    advanced renal
    cell carcinoma:
    results from a                                                  
    phase 1b trial                

    Poster Sessions

    Head and Neck             Lee NY       TPS6093    Monday, June 5  Head and Neck Cancer
    Cancer (TiP)                                      1:15-4:45 p.m.
    (JAVELIN Head and
    Neck 100)

    JAVELIN Head and
    Neck 100: a phase
    3 trial of
    avelumab in
    combination with
    (CRT) vs CRT for
    treatment of
    locally advanced                           
    squamous cell
    carcinoma of the
    head and neck (LA

    Lymphoma (TiP)            Chen R      TPS7575    Monday, June 5            Hematologic
    (JAVELIN DLBCL)                                 8:00-11:30 a.m.  Malignancies-Lymphoma
                                                                    and Chronic Lymphocytic
    Phase 1b/3 study                                                              Leukemia
    of avelumab-based
    regimens in                                                 
    patients (pts)                                             
    with relapsed or                           
    diffuse large
    B-cell lymphoma
    (R/R DLBCL)
    Merkel Cell          D'Angelo SP        9530  Saturday, June 3   Melanoma/Skin Cancers
    Carcinoma                                       1:15-4:45 p.m.
    (JAVELIN Merkel

    treatment in
    patients with
    metastatic Merkel                         
    cell carcinoma:
    preliminary data
    from an ongoing
     Merkel Cell            Shapiro I        9557  Saturday, June 3   Melanoma/Skin Cancers
    Carcinoma                                       1:15-4:45 p.m.
    (JAVELIN Merkel

    analysis in
    patients with
    refractory metastatic
    Merkel cell
    carcinoma treated
    with avelumab           

    Non-Small Cell         Gulley JL        9086  Saturday, June 3   Lung Cancer-Non-Small
    Lung Cancer                                    8:00-11:30 a.m.         Cell Metastatic
    (JAVELIN Solid

    and PD-L1
    analysis of
    avelumab in
    patients with
    advanced NSCLC:
    data from the
    JAVELIN Solid                                               
    Tumor trial

    Pan-Tumor                Kelly K        3059    Monday, June 5          Developmental
    (JAVELIN Solid                                 8:00-11:30 a.m.          Therapeutics-
    Tumor)                                                                  Immunotherapy

    Safety profile of
    avelumab in
    patients with
    advanced solid
    tumors: a JAVELIN
    pooled analysis                                                 
    of phase 1 and 2                                           

    Prostate Cancer   Fakhrejahani F        5037    Monday, June 5         Genitourinary
    (JAVELIN Solid                                    1:15-4:45 PM     (Prostate) Cancer

    Avelumab in
    ant prostate                                        
    cancer (mCRPC)                   

     Renal Cell           Choueiri TK      TPS4594  Sunday, June 4          Genitourinary
    Carcinoma                                     8:00-11:30 a.m.          (Nonprostate)
    (JAVELIN Renal

    Avelumab plus
    axitinib vs
    sunitinib as
    treatment of                                                    
    advanced renal                             
    cell carcinoma:
    phase 3 study
    (JAVELIN Renal

    Urothelial              Apolo AB        4528   Sunday, June 4         Genitourinary
      Carcinoma                                     8:00-11:30 a.m.  (Nonprostate) Cancer
    (JAVELIN Solid

    Updated efficacy
    and safety of                                                   
    avelumab in
    carcinoma: pooled                          
    analysis from 2
    cohorts of the
    phase 1b JAVELIN
    Solid Tumor study


     Merkel Cell            Bharmal M      e21070
    (JAVELIN Merkel

    during avelumab
    treatment is
    associated with
    improvements in
    quality of life
    in patients with
    Merkel cell

     Merkel Cell           Kaufman HL      e21065
    (JAVELIN Merkel

    experiences with
    avelumab vs
    chemotherapy for
    treating Merkel
    cell carcinoma:
    results from

    Non-Small Cell            Feng Z      e20581
    Lung Cancer
    (JAVELIN Solid

    Comparative study
    of two PD-L1
    expression assays
    in patients with
    non-small cell
    lung cancer

*Avelumab is under clinical investigation for treatment of NSCLC, RCC, DLBCL, SSCHN and mCRPC and has not been demonstrated to be safe and effective for these indications. There is no guarantee that avelumab will be approved for NSCLC, RCC, DLBCL, SSCHN and mCRPC by any health authority worldwide.

About Avelumab 

Avelumab is a human antibody specific for a protein called PD-L1, or programmed death ligand-1. Avelumab is designed to potentially engage both the adaptive and innate immune systems. By binding to PD-L1, avelumab is thought to prevent tumor cells from using PD-L1 for protection against white blood cells, such as T-cells, exposing them to anti-tumor responses. Avelumab has been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. In November 2014, Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize avelumab.


The US Food and Drug Administration (FDA) granted accelerated approval for avelumab (BAVENCIO®) for the treatment of (i) metastatic Merkel cell carcinoma (mMCC) in adults and pediatric patients 12 years and older and (ii) patients with locally advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. Avelumab is not approved for any indication in any market outside the US.

Important Safety Information  

The warnings and precautions for BAVENCIO include immune-mediated adverse reactions (such as pneumonitis, hepatitis, colitis, endocrinopathies, nephritis and renal dysfunction and other adverse reactions), infusion-related reactions and embryo-fetal toxicity.

Common adverse reactions (reported in at least 20% of patients) in patients treated with avelumab include fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reaction, peripheral edema, decreased appetite/hypophagia, urinary tract infection and rash.

About the Merck-Pfizer Alliance 

Immuno-oncology is a top priority for Merck and Pfizer Inc. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other's strengths and capabilities and further explore the therapeutic potential of avelumab, an anti-PD-L1 antibody initially discovered and developed by Merck. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer's PD-1 antibody. The alliance is focused on developing high-priority international clinical programs to investigate avelumab as a monotherapy, as well as in combination regimens, and is striving to find new ways to treat cancer.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to to register online, change your selection or discontinue this service.

For further details and press materials about Merck in oncology please visit

About Merck 

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the "Merck" name and brand except in the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Pfizer Inc.: Working together for a healthier world® 

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at In addition, to learn more, please visit us at and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at

Pfizer Disclosure Notice 

The information contained in this release is as of May 17, 2017. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about BAVENCIO (avelumab), the Merck-Pfizer Alliance involving anti-PD-L1 and anti-PD-1 therapies, and clinical development plans, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of BAVENCIO; the uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and completion dates and regulatory submission dates, as well as the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether; whether and when drug applications may be filed in any jurisdictions for potential indications for BAVENCIO, combination therapies or other product candidates; whether and when any such applications (including the pending application for BAVENCIO for metastatic Merkel cell carcinoma in the EU) may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of BAVENCIO, combination therapies or other product candidates; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at and

Your Contacts Merck Media Gangolf Schrimpf +49-6151-72-9591 Investor Relations                       +49-6151-72-3321 Pfizer Media (US) Sally Beatty +1-212-733-6566 Media (EU) Lisa O'Neill +44-1737-331536 Investor Relations Ryan Crowe +1-212-733-8160


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store